ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer

Correlate tumor mutation burden with immune signatures in human cancers

(2019) Xiaosheng Wang et al.   BMC IMMUNOLOGY

Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer

(2019) Young-Bae Kim et al.   INTERNATIONAL JOURNAL OF CANCER

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment

(2019) Zehang Jiang et al.   EBioMedicine

TISIDB: an integrated repository portal for tumor-immune system interactions

(2019) Beibei Ru et al.   BIOINFORMATICS

Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer

(2018) Yi Ping Zhu et al.   HUMAN PATHOLOGY

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

(2018) Jianfeng Shen et al.   NATURE MEDICINE

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

(2018) Deng Pan et al.   SCIENCE

The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression

(2018) Simonetta Buglioni et al.   OncoImmunology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer

(2018) Zehang Jiang et al.   Translational Oncology

Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells

(2018) Changjie Wu et al.   Nature Communications

DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers

(2018) Juan Ruiz-Bañobre et al.   GASTROENTEROLOGY

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study

(2017) Yoshihiko Tomita et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

(2017) Joshua Bauml et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

(2017) Teresa Davoli et al.   SCIENCE

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice

(2016) Radhika Mathur et al.   NATURE GENETICS

KEGG: new perspectives on genomes, pathways, diseases and drugs

(2016) Minoru Kanehisa et al.   NUCLEIC ACIDS RESEARCH

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

(2016) Chris T. Williamson et al.   Nature Communications

Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies

(2016) Lin Yang et al.   Scientific Reports

Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency

(2016) Nayoung Han et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Potential therapeutic targets inARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Loss of Tumor Suppressor ARID1A Protein Expression Correlates with Poor Prognosis in Patients with Primary Breast Cancer

(2015) Hyun Deuk Cho et al.   Journal of Breast Cancer

Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma

(2015) Fei He et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

(2015) Razvan Cristescu et al.   NATURE MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

(2015) J. Shen et al.   Cancer Discovery

Loss of ARID1A Expression in Gastric Cancer: Correlation with Mismatch Repair Deficiency and Clinicopathologic Features

(2015) Kyung-Ju Kim et al.   Journal of Gastric Cancer

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas

(2013) Ghassan Allo et al.   MODERN PATHOLOGY

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Absolute quantification of somatic DNA alterations in human cancer

(2012) Scott L Carter et al.   NATURE BIOTECHNOLOGY

New drug shows promise in refractory colorectal cancer

(2012) Rebecca Kirk   Nature Reviews Clinical Oncology